180
Participants
Start Date
July 6, 2023
Primary Completion Date
July 30, 2024
Study Completion Date
December 30, 2024
LP-003 dose 1
Liquid in vial
LP-003 dose 2
Liquid in vial
Placebo
Liquid in vial
RECRUITING
Beijing Shijitan Hospital, Beijing
NOT_YET_RECRUITING
Dongfang Hospital, Beijing
NOT_YET_RECRUITING
Peking Union Medical College Hospital, Beijing
NOT_YET_RECRUITING
Peking University Third Hospital, Beijing
NOT_YET_RECRUITING
Zhengzhou central hospital, Zhengzhou
NOT_YET_RECRUITING
Changchun University of Chinese Medicine Affiliated Hospital, Changchun
NOT_YET_RECRUITING
Tonghua central hospital, Tonghua
NOT_YET_RECRUITING
Yan Bian Chao Yi Hospital, Yanbian
NOT_YET_RECRUITING
Yanbian University hospital, Yanji
NOT_YET_RECRUITING
Shengjing Hospital of China Medical University, Shenyang
NOT_YET_RECRUITING
Yinchuan Peoples Hospital, Yinchuan
NOT_YET_RECRUITING
Zibo central hospital, Zibo
NOT_YET_RECRUITING
Linfen Peoples Hospital, Linfen
NOT_YET_RECRUITING
Second hospital of Shanxi Medical University University, Taiyuan
NOT_YET_RECRUITING
The First Hospital of Shanxi Medical University, Taiyuan
NOT_YET_RECRUITING
Xidian group hospital, Xi’an
NOT_YET_RECRUITING
Tianjin Peoples Hospital, Tianjing
Lead Sponsor
Longbio Pharma
INDUSTRY